knowledge -WSS

knowledge

author：explore 2025-09-03 03:46:13 - browse：6

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： An inside look at PIPEs, biotech's buzzy new financing tool

leisure time

WSS

In search for therapies for solid tumors, companies turn to claudin

Pfizer highlights cancer drugs it thinks could reignite investor interest

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Congress gives doctors Medicare pay bump

Medical device lobby: We're tired of waiting on Medicare coverage

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Flu vaccine offering decent levels of protection this winter, new data show

Moonlake's readout produced a cash windfall. Risks remain

Medical device lobby: We're tired of waiting on Medicare coverage

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

Dobbs anniversary: the lost opportunity of abortion as health care

Scientists unlock the key to scar

DIEP, the 'gold standard' of breast reconstruction, is under threat

Covid isolation guidance eased by the CDC

knowledge

Kenai launches with $82 million for Parkinson’s stem cell therapy

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

RaDonda Vaught to speak at CommonSpirit event on patient safety

Kenai launches with $82 million for Parkinson’s stem cell therapy

Medical device lobby: We're tired of waiting on Medicare coverage

In search for therapies for solid tumors, companies turn to claudin

explore

leisure time

focus

focus